News | September 05, 2024
Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated
